Filing Flows › Edwards Lifesciences (EW) › Transcatheter Mitral and Tricuspid Therapies revenue
Edwards Lifesciences (EW) Transcatheter Mitral and Tricuspid Therapies revenue by quarter
Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies revenue was $210M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 7 quarters it ranged from $115M (Q1 2025) to $210M (Q3 2026).
| Quarter | Transcatheter Mitral and Tricuspid Therapies revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $210M | +5% | +44% |
| Q2 2026 | $199M | +13% | +48% |
| Q1 2026 | $175M | +12% | +52% |
| Q4 2025 | $156M | +7% | — |
| Q3 2025 | $145M | +8% | — |
| Q2 2025 | $134M | +17% | — |
| Q1 2025 | $115M | — | — |
Q3 2026 at a glance
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
Questions
What is Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies revenue?
Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies revenue was $210M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies revenue changed?
Over the last 7 quarters it ranged from $115M (Q1 2025) to $210M (Q3 2026).